DEPEND stands for Dosage and Efficacy of Probucol-induced apoE to Negate cognitive Deterioration.
This proof-of-concept program, in two phases, was intended to study the effect of probucol, an old cholesterol-lowering drug on apoE protein levels in cerebrospinal fluid and on other vascular biomarkers in blood and CSF.
Phase A – 23 participants – COMPLETED
Phase B – not started
Clinical trial.gov NCT02707458